Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4604 in moderate-to-severe asthma
NCT06020014Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing AZD4604 with Placebo (2 arms). Primary endpoint: Time to first Composite Exacerbation Asthma Event at 12 weeks. Started Nov 2023; status: completed.
02
Drugs
londamocitinib
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06020014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06020014.